促肾上腺皮质激素治疗高进展风险IgA肾病的开放标签初步研究
这项前瞻性开放标签初步研究纳入19例24小时尿蛋白>1g且eGFR>30ml/min的IgA肾病患者,给予促肾上腺皮质激素(ACTH)80单位皮下注射每周两次共6个月,随访12个月。结果显示24小时尿蛋白从2.6g降至1.3g(P=0.007),血清白蛋白从3.79升至3.93(P=0.02),eGFR无显著变化(65.5至61.1ml/min,P=0.1),8例(42%)达部分缓解,无完全缓解,共发生6例感染。
要点
- ACTH治疗6个月可显著降低高进展风险IgA肾病患者24小时尿蛋白。
- 12个月随访时eGFR保持稳定,部分缓解率为42%。
- 治疗期间感染发生6例,最常见不良事件包括痤疮、潮热、酸痛和焦虑。
核心结论
- 对于24小时尿蛋白>1g且eGFR>30ml/min的IgA肾病患者,ACTH治疗6个月后随访12个月,24小时尿蛋白显著降低且eGFR稳定。
研究设计与样本
- 前瞻性开放标签初步研究,共招募19例IgA肾病患者并随访1年。
- ACTH剂量为80单位皮下注射每周两次,总疗程6个月,随访共12个月。
- 入组条件为尽管充分RAAS阻断仍24小时尿蛋白>1g且eGFR>30ml/min。
主要发现
- 12个月时24小时尿蛋白从2.6g降至1.3g(P=0.007)。
- 血清白蛋白从3.79升至3.93(P=0.02)。
- eGFR从65.5ml/min降至61.1ml/min,无统计学显著性(P=0.1)。
- 0例完全缓解,8例部分缓解(42%)。
- 共发生6例感染:2例病毒性,4例需抗生素治疗(2例鼻窦炎、1例肺炎、1例中耳炎)。
关键数值与推荐
- 入组标准:24小时尿蛋白>1g且eGFR>30ml/min,尽管充分RAAS阻断。
- ACTH用法:80单位皮下注射每周两次,共6个月。
- 部分缓解定义为24小时尿蛋白下降但未达完全缓解标准,本研究中8例(42%)达部分缓解。
临床怎么用
- 对于高进展风险IgA肾病患者,ACTH可能作为降低蛋白尿的治疗选择,但需监测感染等不良反应。
- 治疗期间eGFR保持稳定,但需注意个体化评估获益与风险。
局限性
- 开放标签、非随机、无对照设计。
- 样本量小(19例),随访时间较短(12个月)。
- 缺乏完全缓解病例,部分缓解率需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy (IgAN) is the most common glomerulonephritis with high risk of progression to end-stage renal disease in patients with proteinuria >1 g/24 hours. There are no known effective treatments in patients with IgAN. METHODS: We conducted a prospective open-label pilot study in patients with IgAN using adrenocorticotrophic hormone (ACTH) (Acthar Gel, Mallinckrodt Pharmaceuticals, Bedminster, NJ) at a dosage of 80 units subcutaneously twice weekly for a total of 6 months and followed patients for a total of 12 months. Patients had to have urinary protein >1 g/24 hours despite adequate renin-angiotensin-aldosterone system (RAAS) blockade and estimated glomerular filtration rate (eGFR) >30 ml/min at enrollment. RESULTS: A total of 19 patients were recruited and followed for 1 year. At baseline, the mean age was 34.9 ± 10.5 years with 11 men and 8 women, and 14 Caucasian and 5 Asian individuals. At 12 months, there was a statistically significant decline in 24-hour urinary protein from 2.6 to 1.3 g (P = 0.007) and significant increase in serum albumin (3.79 to 3.93, P = 0.02). There was no significant change in eGFR (65.5 to 61.1 ml/min, P = 0.1). There were 0 complete remissions and 8 partial remissions (42%). There were a total of 6 infections: 2 were viral and 4 required antibiotic therapy (2 sinusitis, 1 pneumonia, 1 otitis media). The most common adverse events included acne, hot flashes, soreness, and anxiety. CONCLUSION: In summary, patients with IgAN with >1 g/24-hour urinary protein and eGFR >30 ml/min had a significant reduction in 24-hour urinary protein with stable eGFR at 12-month follow-up after being treated with 6 months of ACTH.
引用
- Zand L, Canetta P, Lafayette R, et al. An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney Int Rep. 2019. PMID: 31922061. doi:10.1016/j.ekir.2019.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。